Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Beow Yong Yeap, Sc.D.

Co-Author

This page shows the publications co-authored by Beow Yeap and Thomas Delaney.
Connection Strength

1.245
  1. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):85-93.
    View in: PubMed
    Score: 0.173
  2. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014 Aug; 110(2):115-22.
    View in: PubMed
    Score: 0.143
  3. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009 Jul 01; 74(3):732-9.
    View in: PubMed
    Score: 0.099
  4. The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100635.
    View in: PubMed
    Score: 0.057
  5. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.051
  6. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):90-95.
    View in: PubMed
    Score: 0.051
  7. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72.
    View in: PubMed
    Score: 0.050
  8. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol. 2018; 2:22.
    View in: PubMed
    Score: 0.049
  9. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969.
    View in: PubMed
    Score: 0.048
  10. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1222-1225.
    View in: PubMed
    Score: 0.047
  11. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  12. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
  13. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014 Oct; 113(1):89-94.
    View in: PubMed
    Score: 0.037
  14. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014 Dec 01; 120(23):3676-82.
    View in: PubMed
    Score: 0.037
  15. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.036
  16. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):316-322.
    View in: PubMed
    Score: 0.035
  17. ß-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013; 18(9):1043-9.
    View in: PubMed
    Score: 0.034
  18. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):484-90.
    View in: PubMed
    Score: 0.033
  19. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013 Mar; 49(4):875-83.
    View in: PubMed
    Score: 0.032
  20. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012 Dec; 19(13):4028-35.
    View in: PubMed
    Score: 0.032
  21. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013 Jan; 20(1):80-6.
    View in: PubMed
    Score: 0.032
  22. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1142-8.
    View in: PubMed
    Score: 0.030
  23. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):151-7.
    View in: PubMed
    Score: 0.027
  24. Phase I study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. J Clin Oncol. 2009 May 20; 27(15_suppl):e15536.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.